Literature DB >> 25232442

High-sensitivity to heparin associates with cell salvage transfusion in adolescent idiopathic scoliosis patient undergoing posterior spinal fusion.

Li Du1, Jianqiao Zheng2, Yumin Tang1.   

Abstract

A 16-year-old male with adolescent idiopathic scoliosis was scheduled for the posterior spinal fusion (PSF) under general anesthesia. The cell saver was routinely prepared preoperatively and 400 ml of salvaged red blood cells were transfused during the surgery. After the cell salvage transfusion, the oozing of blood in surgical wounds occurred and the activated coagulation time (ACT) of the arterial blood was 999 s, considering the possibility of the residual heparin in the cell salvage, 30 mg of protamine was injected intravenously, 5 min later the ACT dropped to 125 s. After the therapy, the surgical procedure was performed successfully. After the procedure was over, the patient went back to the ward with normal coagulation function indicators. 11 days later, the patient was discharged home without complications. We present this case of coagulopathy caused by minor cell salvage transfusion and wish to highlight the importance of the blood coagulation monitoring that can be overlooked in these situations.

Entities:  

Keywords:  Cell saver; adolescent idiopathic scoliosis; coagulopathy; heparin hypersensitive; posterior spinal fusion

Year:  2014        PMID: 25232442      PMCID: PMC4161602     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  11 in total

Review 1.  Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.

Authors:  R J Simko; F F Tsung; E J Stanek
Journal:  Ann Pharmacother       Date:  1995-10       Impact factor: 3.154

2.  Heparin washout in the pediatric Cell Saver bowl.

Authors:  J J Sistino; D Owitz; L B Mongero
Journal:  J Extra Corpor Technol       Date:  1992

Review 3.  The use of activated clotting times to monitor heparin therapy during and after interventional procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Clin Cardiol       Date:  1994-07       Impact factor: 2.882

4.  Towards bloodless cystectomy: a 10-year experience of intra-operative cell salvage during radical cystectomy.

Authors:  Jonathan Aning; Jamie Dunn; Mark Daugherty; Robert Mason; Richard Pocock; Biddy Ridler; John Thompson; John S McGrath
Journal:  BJU Int       Date:  2012-07-23       Impact factor: 5.588

Review 5.  Cell salvage for minimising perioperative allogeneic blood transfusion.

Authors:  Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  Coagulopathy associated with massive cell salvage transfusion following aortic surgery.

Authors:  K E Rollins; N L Trim; R J Luddington; S Colah; A Klein; M W Besser; S K Nair
Journal:  Perfusion       Date:  2011-08-22       Impact factor: 1.972

7.  Pre-donated autologous blood transfusion in scoliosis surgery.

Authors:  S Ridgeway; C Tai; P Alton; P Barnardo; D J Harrison
Journal:  J Bone Joint Surg Br       Date:  2003-09

8.  The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.

Authors:  Jonathan D Marmur; Sunil X Anand; Ramanjit S Bagga; Jawed Fareed; Chi-Miau Pan; Samin K Sharma; Merwin F Richard
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

9.  Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?

Authors:  S J Brister; F A Ofosu; M R Buchanan
Journal:  Thromb Haemost       Date:  1993-08-02       Impact factor: 5.249

10.  Coagulopathy associated with cell salvage transfusion following cerebrovascular surgery.

Authors:  Jianqiao Zheng; Li Du; Guizhi Du; Bin Liu
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

View more
  1 in total

1.  Impact of intra-operative cell salvage on blood coagulation in high-bleeding-risk patients undergoing cardiac surgery with cardiopulmonary bypass: a prospective randomized and controlled trial.

Authors:  Sheliang Shen; Jun Zhang; Wenyuan Wang; Jiayin Zheng; Yihong Xie
Journal:  J Transl Med       Date:  2016-07-29       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.